 | Harold S NelsonShow email addressNational Jewish Health, Denver, Colorado, USA. | Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado. Electronic ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Harold S Nelson:Expert Impact
Concepts for whichHarold S Nelsonhas direct influence:Allergic rhinitis,Sublingual immunotherapy,Allergen immunotherapy,Inhaled corticosteroids,Fluticasone propionate,Skin testing,Severe asthma,Pulmicort turbuhaler.
Harold S Nelson:KOL impact
Concepts related to the work of other authors for whichfor which Harold S Nelson has influence:Allergic rhinitis,Sublingual immunotherapy,Inhaled corticosteroids,Food allergy,Severe asthma,Fluticasone propionate,Atopic dermatitis.
KOL Resume for Harold S Nelson
| Year | |
|---|---|
| 2021 | National Jewish Health, Denver, Colorado, USA. Denver, CO |
| 2020 | Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado. Electronic address: Department of Medicine, National Jewish Health, Denver, CO, USA; |
| 2019 | National Jewish Health, Denver, Colo. |
| 2018 | National Jewish Health, University of Colorado Denver School of Medicine, Denver, Colorado. Electronic address: |
| 2017 | University of Colorado School of Medicine, Aurora, CO, USA |
| 2016 | Department of Medicine, Allergy/Immunology Division, National Jewish Health, Denver, Colorado. National Jewish Health and University of Colorado Denver School of Medicine, 1400 Jackson Street, Denver, CO 80206, USA |
| 2015 | National Jewish Health, 1400 Jackson Street, Denver, CO 80206, |
| 2014 | National Jewish Health, University of Colorado – Denver School of Medicine, Denver, Colorado, USA |
| 2013 | National Jewish Health Denver CO USA |
| 2012 | National Jewish Health Department of Medicine Division of Allergy and Immunology Denver CO |
| 2011 | Department of Medicine, National Jewish Health and the University of Colorado School of Medicine, Denver, Colorado |
| 2010 | Chief Editor National Jewish Medical and Research Center, Denver, Colorado, USA |
| 2009 | Professor of Pediatrics and Medicine Head, Division of Pediatric Allergy, Immunology and Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison WI, USA National Jewish Medical and Research Center, Denver, Colorado. University of Colorado Health Sciences Center, Denver, Colo |
| 2008 | From University of Cape Town, Cape Town, South Africa; National Jewish Medical and Research Center, Denver, Colorado; Hôpital Arnaud de Villeneuve, Montpellier, France; and GlaxoSmithKline, Research Triangle Park, North Carolina. National Jewish Medical and Research Center, Denver, CO |
| 2007 | From National Jewish Medical and Research Center Southampton General Hospital, Southampton, United Kingdom |
| 2006 | Division of Allergy, National Jewish Medical and Research Center, Denver, Colorado Allergy and Immunology, National Jewish Medical and Research Center, Denver, CO From the National Jewish Medical and Research Center |
| 2005 | National Jewish Medical and Research Center, 1400 Jackson Street, 80206, Denver, CO, USA |
| 2004 | School of Public Health and Primary Health Care, University of Cape Town, Cape Town, South Africa National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206 University of Wisconsin, Madison, WI |
| 2003 | From aNational Jewish Medical and Research Center, Denver; bAsthma and Airway Center of the University Health Network, Toronto; and cGlaxoSmithKline, Greenford National Jewish Medical and Research Center, Denver, CO 80206, USA. Series editor Denver, Colo Department of Pediatrics, University of New Mexico Children's Hospital, Albuquerque, NM, USA |
| 2002 | Department of Medicine, National Jewish Medical Research Center, Denver, CO 80206, USA 1Dept of Environmental and Geographical Sciences, 2Dept of Public Health and Primary Health Care, 3Dept of Medicine and 4Dept of Paediatrics and Child Health, University of Cape Town, Observatory, Cape Town, South Africa |
| Concept | World rank |
|---|---|
| majority droplets | #1 |
| ragweed tablets | #1 |
| 6 12 1u | #1 |
| fev1jpf | #1 |
| doses allergen extract | #1 |
| peak weeks weed | #1 |
| systemic reactions review | #1 |
| formoterol randomized | #1 |
| asthma levalbuterol | #1 |
| sublingual allergen tablets | #1 |
| extracts dilutions | #1 |
| range proven doses | #1 |
| serum levels chlorpheniramine | #1 |
| devices size | #1 |
| systemic bronchodilators | #1 |
| average intradermal tests | #1 |
| ses rhinitis | #1 |
| sar fsc | #1 |
| extracts greatest likelihood | #1 |
| 301 percent | #1 |
| allergen exposure alters | #1 |
| aquatower devilbiss | #1 |
| parijet devilbiss | #1 |
| 1 airway concept | #1 |
| subjects positive spt | #1 |
| maximal suppression subsensitivity | #1 |
| prescribed labas | #1 |
| grass pollen arc | #1 |
| builtin spacer | #1 |
| notable leonard noon | #1 |
| 25 albuterol solution | #1 |
| european allergists | #1 |
| schedule drug allergic | #1 |
| 122 minute | #1 |
| new approaches ait | #1 |
| inhalant 100 years | #1 |
| allergen extracts patient | #1 |
| tto droplets | #1 |
| flow rates nebulization | #1 |
| salsola pestifer | #1 |
| antihistamines development | #1 |
| sgrq assessment | #1 |
| agents catechol adrenergic | #1 |
| diameter rate | #1 |
| corticosteroids symptom control | #1 |
| subsequent epinephrine infusion | #1 |
| multiallergen | #1 |
| atopic dermatitis sequence | #1 |
| duo tiptest | #1 |
| nebulizers 25 | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Harold S Nelson
OBJECTIVE: In a prospective study of children with a family history of asthma, asthma onset by 3 years of age was found previously to be positively associated with variables from the first year of life, including elevated total immunoglobulin E (IgE), frequent respiratory infections, and parenting difficulties. We followed this cohort of genetically at-risk children to investigate the relationship between factors assessed in infancy and asthma, allergy, and psychological status at school ...
| Known for Children Asthma | 6 Years Age | Year Life | Parenting Difficulties | Mothers Infants |
OBJECTIVE: To determine the effects of budesonide and formoterol administered via one pressurized metered-dose inhaler (budesonide/formoterol pMDI) on patient-reported outcomes (PROs) and to determine the contributions of budesonide and formoterol to those effects in adults with asthma.
RESEARCH DESIGN AND METHODS: A 12-week, randomized, double-blind, double-dummy, placebo-controlled, multicenter study was conducted in 480 patients aged > or = 12 years with mild-to-moderate persistent ...
| Known for Budesonide Formoterol | Patients Asthma | Reported Outcomes | Pressurized Metered | Quality Life |
Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults
[ PUBLICATION ]
BACKGROUND: Immunotherapy for allergic rhinoconjunctivitis (ARC) in North America is generally administered subcutaneously, but alternative formulations might be safer and more convenient. Trials of sublingual formulations in North America are needed to confirm European efficacy and safety data.
OBJECTIVE: We sought to investigate the efficacy and safety of timothy grass allergy immunotherapy tablet (AIT) treatment in North American subjects with ARC.
METHODS: Four hundred thirty-nine ...
| Known for North America | Immunotherapy Tablet | Timothy Grass | Efficacy Safety | Allergic Desensitization |
BACKGROUND: Sensitivity and exposure to indoor allergens constitutes a risk factor for the development and persistence of asthma in children.
OBJECTIVE: Our purpose was to evaluate the relationship between sensitivity and exposure to inhalant allergens and lung function and bronchial responsiveness in a group of children (n = 1041) aged 8.9 +/- 2.1 years with mild to moderate asthma enrolled in the Childhood Asthma Management Program (CAMP).
METHODS: With use of the extensive CAMP ...
| Known for Bronchial Hyperresponsiveness | Pulmonary Function | Asthma Management | Allergen Sensitization | Skin Testing |
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler
[ PUBLICATION ]
A new formulation of mometasone furoate (MF) for administration by dry powder inhaler (DPI) was evaluated for the treatment of asthma. A 12-week, double-blind, placebo-controlled dose-ranging study compared the efficacy and safety of three doses of MF DPI (100, 200 and 400 mcg b.i.d) with beclomethasone dipropionate (BDP) 168 mcg b.i.d. administered by metered dose inhaler in 365 adult or adolescent patients being treated with inhaled glucocorticoids. The mean change from baseline to ...
| Known for Mf Dpi | Mometasone Furoate | Treatment Asthma | Dry Powder | Pulmonary Function |
Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial
[ PUBLICATION ]
BACKGROUND: Ragweed sublingual immunotherapy (SLIT) tablet reduces symptoms and symptom-relieving medication use in adults with allergic rhinitis with or without conjunctivitis (AR/C) but has not been evaluated in children.
OBJECTIVE: This international, multicenter, double-blind, placebo-controlled trial evaluated the efficacy and safety of ragweed SLIT-tablet in children with AR/C.
METHODS: Children (N = 1025; 77.7% polysensitized) aged 5 to 17 years with ragweed pollen-induced AR/C ...
| Known for Ragweed Slit | Peak Rps | Efficacy Safety | Dss Dms | Preschool Conjunctivitis |
BACKGROUND: The house dust mite (HDM) sublingual immunotherapy (SLIT) tablet (MK-8237; Merck & Co, Kenilworth, NJ/ALK-Abelló, Hørsholm, Denmark) has demonstrated beneficial effects on allergic rhinoconjunctivitis and asthma outcomes in European trials.
OBJECTIVE: This is the first trial to assess the efficacy/safety of HDM SLIT-tablets in North American subjects with HDM-induced allergic rhinitis with or without conjunctivitis (AR/C).
METHODS: In this double-blind, multicenter trial ...
| Known for House Dust | Immunotherapy Tablet | Animals Antigens | Mite Sublingual | Rhinitis Allergic |
Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control
[ PUBLICATION ]
BACKGROUND: Asthma and allergic rhinitis are both highly prevalent diseases and often coexist in patients.
OBJECTIVE: To investigate the effect of rhinitis therapy on asthma outcomes in adult and adolescent patients with both seasonal allergic rhinitis (SAR) and persistent asthma.
METHODS: A total of 863 patients (mean baseline FEV1 81% predicted) were randomized to receive open-label fluticasone propionate/salmeterol (FSC), 100/50 microg bid for 4 weeks, plus either blinded fluticasone ...
| Known for Asthma Control | Fsc Fpans | Fluticasone Propionate | Nasal Spray | Placebo Patients |
BACKGROUND: Asthma is a disease of chronic inflammation and bronchoconstriction. Inhaled corticosteroids (ICSs) provide important anti-inflammatory treatment but may not provide optimal control of asthma when taken alone. Two therapeutic alternatives for enhanced asthma control are to substitute the combination of fluticasone propionate (FP) and salmeterol (FP/Salm Combo) through the Diskus inhaler or to add montelukast to existing ICS therapy.
OBJECTIVE: We compared the efficacy and ...
| Known for Salmeterol Combination | Montelukast Patients | Fluticasone Propionate | Asthma Control | Ics Therapy |
Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy
[ PUBLICATION ]
BACKGROUND: Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have been shown to effectively treat grass pollen allergies, although direct comparisons are sparse.
OBJECTIVE: To estimate the relative efficacy of SLIT tablets compared with SCIT and SLIT drops in commercially available products though network meta-analysis.
METHODS: A literature search of MEDLINE, Embase, and Cochrane Library publications. Randomized, double-blind clinical trials of SCIT, SLIT drops, and ...
| Known for Slit Tablets | Network Meta | Subcutaneous Immunotherapy Scit | Smd 95 | Medication Scores |
BACKGROUND: Many patients with severe asthma are dependent on oral corticosteroids for maintenance control of their disease. Treatments that allow patients to be weaned off oral corticosteroids may help to minimize the risk of side effects associated with their chronic use.
OBJECTIVE: This study evaluated whether inhaled fluticasone propionate powder could maintain pulmonary function while reducing the dose of oral prednisone in patients with chronic, severe asthma.
METHODS: Oral ...
| Known for Chronic Asthma | Oral Prednisone | Fluticasone Propionate | Lung Function | Inhalation Administration |
BACKGROUND: Salmeterol, a long-acting beta2 -agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients.
OBJECTIVE: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma.
METHODS: This was a randomized, double-blind, double-dummy, parallel-group, multicenter clinical trial. Patients, over 80% of whom were on a ...
| Known for Inhaled Salmeterol | Oral Zafirlukast | Treatment Asthma | Inhalation Administration | 4 Weeks |
Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys
[ PUBLICATION ]
Allergic rhinitis (AR; also nasal allergies or "hay fever") is a chronic upper airway inflammatory disease that affects ∼60 million adults and children in the United States. The duration and severity of AR symptoms contribute to a substantial burden on patients' quality of life (QoL), sleep, work productivity, and activity. This study was designed to examine symptoms, QoL, productivity, comorbidities, disease management, and pharmacologic treatment of AR in United States and ex-U.S. ...
| Known for Allergic Rhinitis | Latin America | United States | Life Qol | Work Productivity |
A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract
[ PUBLICATION ]
BACKGROUND: Allergen immunotherapy with doses of cat extract containing approximately 15 microg of the major allergen, Fel d 1, have been proved clinically effective in several double-blind, placebo-controlled studies. However, the maintenance doses used in allergy practice in the United States are often considerably less than this proven dose.
OBJECTIVE: The purpose of this investigation was to determine whether maintenance immunotherapy with cat dander extract containing 0.6 microg or ...
| Known for Allergen Immunotherapy | Maintenance Dose | Dander Extract | Immunologic Response | Skin Tests |
